56 results
8-K
EX-99.1
BTTX
Better Therapeutics Inc
11 Mar 24
Regulation FD Disclosure
9:01am
the power of behavior change. Many of the most common (and costly) chronic diseases share lifestyle behaviors that contribute to disease progression … the first, multi-billion dollar Prescription Digital Therapeutics company Type 2 Diabetes is the most expensive chronic condition in the US ($400B+ annually
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
in chronic condition management, today announced a partnership to integrate Better Therapeutics’ AspyreRx ™ digital behavioral treatment for type 2 … outcomes of people with chronic conditions through its personalized, intelligent, connected care platforms. Our proven technologies make lives better
8-K
EX-99.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today … for patients who may benefit from this innovative new treatment.”
About Glooko
Glooko improves health outcomes of people with chronic conditions
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
and costly chronic diseases that are largely reversible and preventable, offering opportunities for transformative impact and 3) represent areas … Dysfunction-Associated Steatotic Liver Disease (“MASLD”), Metabolic Dysfunction-Associated Steatohepatitis (“MASH”), and chronic kidney disease
424B5
k2tvxn3m gnh
9 Aug 23
Prospectus supplement for primary offering
4:37pm
424B5
pheg3c
26 Jul 23
Prospectus supplement for primary offering
5:04pm
8-K
EX-99.1
6a1vl1t2kw svo
12 Jul 23
Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes
12:00am
424B5
uhhdkg61 u7f
11 May 23
Prospectus supplement for primary offering
5:20pm